Hims & Hers Health's Next Act: Making Its Own Drugs Again

Hims & Hers reported 2Q revenue up 38% to $753.2M and raised full-year guidance to $3.1–$3.3B. Despite the update, gross margin fell 6 percentage points sequentially to 64%, reflecting the shift toward distributing branded weight-loss drugs (a lower-margin “buy revenue with margin” model). The net impact is a positive growth/outlook setup, partially offset by margin compression.

Analysis

The market should read this less as a pure growth print and more as a business-model transition: HIMS is effectively becoming a paid acquisition and fulfillment layer for branded obesity drugs. That is strategically useful because it lowers regulatory and reputational overhang versus compounding, but it also means the economic moat shifts from product differentiation to distribution efficiency and CAC discipline. The biggest second-order winners are upstream branded GLP-1 manufacturers such as NVO and LLY, while any telehealth or compounding-adjacent competitors lose the ability to compete on price if HIMS normalizes the channel.

The margin compression is the key tell. Revenue can compound quickly while EBITDA quality degrades if the company is buying growth through mix shift and higher traffic costs; that tends to support the stock for 1-2 quarters, then cap the multiple once investors model lower incremental conversion. Over the next 1-3 months, the critical question is whether prescription volume is sticky enough to offset the lower gross profit per user; over 6-18 months, the risk is that branded GLP-1 access becomes less exclusive and the platform loses pricing power.

Contrarian take: the consensus may still be underwriting HIMS like a software-like consumer growth story, but this is increasingly a margin business with a health-care wrapper. If branded drug supply normalizes, payer coverage expands, or the company has to spend harder to defend share, the revenue narrative can decelerate fast. The thesis is falsified if gross margin stabilizes or expands next quarter while EBITDA guidance is raised again; absent that, the stock is more vulnerable to a multiple reset than the headline revenue growth suggests.

Key Decisions for Investors

• Maintain a tactical long only on pullbacks in HIMS, but size it smaller than a normal growth position until gross margin stabilizes; use a stop on a sustained break below the post-earnings breakout level or a sequential gross margin print below the low-60s.
• Pair trade: long NVO or LLY against short HIMS for 1-3 months if you want exposure to GLP-1 demand without taking HIMS margin risk; the structural winner is the drug owner, not the distributor.
• If already long HIMS, consider buying a 1-2 month put spread into the next earnings window as a hedge against another gross-margin leg down; this is a cleaner expression than outright shorting because momentum can remain strong until the next guidance check.
• Watch the next quarter’s contribution margin and CAC/payback metrics; if management can’t show that branded GLP-1 mix is improving retention rather than just monetizing one-time demand, trim the position even if revenue stays strong.
• Set an alert for any signal that branded GLP-1 access broadens through insurers or retail channels; that would compress HIMS’s take-rate and is the main catalyst that could break the bull case within 6-12 months.